There are 2789 resources available
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
350P - Molecular profiling of tumor tissue and tumor-derived cell lines in patients with glioblastoma
Presenter: Tatiana Nasedkina
Session: ePoster Display
300P - Mutational patterns across breast cancer subtypes during metastatic disease progression
Presenter: Hao Liao
Session: ePoster Display
248P - The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry
Presenter: Marissa Meegdes
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display